聚焦治疗与根治性前列腺切除术治疗非转移性前列腺癌的倾向评分匹配研究
本研究基于前瞻性多中心数据库,将761例聚焦治疗(FT)与572例根治性前列腺切除术(RP)患者按1:1倾向评分匹配,比较非转移性低-中危前列腺癌的肿瘤学结局。匹配后各246例,8年无失败生存率(FFS)FT为83%、RP为79%(p=0.12),两组间无显著差异。
要点
- 聚焦治疗与根治性前列腺切除术在8年无失败生存率上无显著差异。
- 匹配后FT组8年FFS为83%,RP组为79%,p=0.12。
- 研究限于PSA<20 ng/ml、Gleason≤4+3、分期≤T2c的低-中危患者。
核心结论
- 在非转移性低-中危前列腺癌患者中,聚焦治疗与根治性前列腺切除术的8年肿瘤学结局相似。
研究设计与样本
- 纳入标准为PSA<20 ng/ml、Gleason≤4+3、分期≤T2c,按治疗年份、年龄、PSA、Gleason评分、T分期、癌芯长度及新辅助激素使用进行1:1倾向评分匹配。
- 聚焦治疗包括1-2次治疗,其中420例为HIFU,81例为冷冻治疗。
- 匹配后共246对病例,RP组平均年龄63.4(5.6)岁,中位PSA 7.9 g/ml(IQR 6-10),中位随访64(30-89)个月;FT组分别为63.3(6.9)岁、7.9 ng/ml(IQR 5.5-10.6)和49(34-67)个月。
主要发现
- 3年、5年和8年无失败生存率(FFS)(95%CI)在RP组分别为86%(81-91%)、82%(77-88%)和79%(73-86%),在FT组分别为91%(87-95%)、86%(81-92%)和83%(76-90%)。
- 两组FFS差异无统计学意义(p=0.12)。
临床怎么用
- 对于非转移性低-中危前列腺癌患者,聚焦治疗可作为根治性前列腺切除术的替代选择之一,8年肿瘤学结局相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Focal therapy (FT) ablates areas of prostate cancer rather than treating the whole gland. We compared oncological outcomes of FT to radical prostatectomy (RP). METHODS: Using prospective multicentre databases of 761 FT and 572 RP cases (November/2005-September/2018), patients with PSA < 20 ng/ml, Gleason </= 4 + 3 and stage </= T2c were 1-1 propensity score-matched for treatment year, age, PSA, Gleason, T-stage, cancer core length and use of neoadjuvant hormones. FT included 1-2 sessions. Primary outcome was failure-free survival (FFS) defined by need for salvage local or systemic therapy or metastases. Differences in FFS were determined using Kaplan-Meier analysis with log-rank test. RESULTS: 335 radical prostatectomy and 501 focal therapy patients were eligible for matching. For focal therapy, 420 had HIFU and 81 cryotherapy. Cryotherapy was used predominantly for anterior cancer. After matching, 246 RP and 246 FT cases were identified. For radical prostatectomy, mean (SD) age was 63.4 (5.6) years, median (IQR) PSA 7.9 g/ml (6-10) and median (IQR) follow-up 64 (30-89) months. For focal therapy, these were 63.3 (6.9) years, 7.9 ng/ml (5.5-10.6) and 49 [34-67] months, respectively. At 3, 5 and 8 years, FFS (95%CI) was 86% (81-91%), 82% (77-88%) and 79% (73-86%) for radical prostatectomy compared to 91% (87-95%), 86% (81-92%) and 83% (76-90%) following focal therapy (p = 0.12). CONCLUSIONS: In patients with non-metastatic low- intermediate prostate cancer, oncological outcomes over 8 years were similar between focal therapy and radical prostatectomy.
引用
- Shah TT, Reddy D, Peters M, et al. Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. Prostate Cancer Prostatic Dis. 2021. PMID: 33504940. doi:10.1038/s41391-020-00315-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。